Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01195571
Other study ID # 1
Secondary ID
Status Completed
Phase Phase 1
First received September 2, 2010
Last updated May 18, 2015
Start date September 2010
Est. completion date October 2014

Study information

Verified date May 2015
Source CMV Research Foundation
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this research study is to test the safety and tolerability of four new investigational Cytomegalovirus (CMV) vaccines (Towne-Toledo 1, 2, 3, 4) in healthy male volunteers who are CMV negative. CMV is a common virus, infecting 50-80% of adults in the United States by the age of twenty-one. CMV does not usually cause illness in adults or children. However, CMV can be a cause of deafness and mental retardation in a child if a mother is infected during pregnancy. It also can be a serious illness in patients with impaired immunity (decreased ability to fight infection).


Description:

A total of thirty six participants will be enrolled. The first 12 participants will be randomized into four groups. Four groups will receive one of the four investigational vaccines. The four investigational HCMV vaccine candidates will be administered subcutaneously to 3 volunteers at 10 pfu (the lowest dose to be used). The safety and tolerability of the four investigational HCMV vaccine candidates will be monitored closely for a period of 12 weeks following vaccination at this dose. Investigational vaccines that are found to be safe and well tolerated at a dose of 10pfu will be administered to 3 additional individuals at 102 pfu and then at 103 pfu. Safety and tolerability will be evaluated at each dose level by monitoring clinical signs and symptoms, laboratory parameters and virus detection in the blood, urine, and saliva. After the 12-week safety-monitoring period, participants will be followed for the remainder of one year to assess long-term safety and immunogenicity of the investigational vaccines.


Recruitment information / eligibility

Status Completed
Enrollment 36
Est. completion date October 2014
Est. primary completion date October 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 30 Years to 50 Years
Eligibility Inclusion Criteria:

- a) Healthy male adult, between the ages of 30 to 50 years with no children <18 years of age at home and in a stable sexual or household relationship with an individual who must be CMV seropositive, non-pregnant, not planning a pregnancy within one year and not currently breastfeeding.

b) HCMV seronegative. c) HIV seronegative. d) Hepatitis B surface antigen negative. e) No evidence of active hepatitis C infection by serologic evaluation. f) HCMV culture negative (to be determined by shell vial or routine culture of urine, blood and saliva collected at the screening visit).

g) Agrees to abstain from sex or to use condoms during intercourse for 52 weeks following vaccination.

h) Available by telephone or pager for one year following vaccination. i) Willing and able to comply with the requirements of the protocol and to properly complete participant diaries.

j) Signed informed consent and completed social/demographic questionnaire. k) Willing to forego blood, bone marrow or whole organ donation for 1year post vaccination.

l) Willing to forego enrollment in studies of other investigational agents for one year following vaccination.

Exclusion Criteria:

1. History of immunodeficiency or any ongoing serious disease such as cancer, autoimmune disease, HIV infection, chronic renal failure (whether or not on dialysis), or diabetes.

2. Significant acute or chronic infection at the time of vaccination.

3. Household contact with an immunosuppressed individual.

4. History of anaphylaxis or severe vaccine reaction.

5. Vaccination with a live vaccine within the past month or an inactivated vaccine within two weeks prior to vaccination, or plan to receive any vaccine within two months following vaccination.

6. Seropositive sexual partner who desires to become pregnant within one year following vaccination, currently is pregnant, or is currently breast feeding.

7. Has a close contact who is CMV seronegative or who is ineligible or chooses not to participate in the study.

8. Received blood products in proceeding three months or expects to receive blood products within the following year.

9. A childcare provider.

10. A health care provider who routinely comes in contact with pregnant women or immunologically compromised persons.

11. Any condition which, in the opinion of the investigator, may interfere with adherence to the protocol or make it inadvisable to enroll the participant.

12. Currently participating in a study of any other experimental or investigational agent, or has participated in such a study within a month of vaccination.

13. Previous vaccination with an investigational HCMV vaccine.

14. Treatment with excluded antiviral or immunosuppressive drugs (Appendix D) within one month prior to vaccination.

15. Expected use of antiviral or immunosuppressive agents within two months following vaccination.

16. Any screening safety laboratory value that is outside normal limits of the laboratory normal range (screening laboratory tests may be repeated if minor abnormalities or possible laboratory errors are noted).

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
cmv vaccine
dose escalation study of 4 towne-toledo chimera vaccines

Locations

Country Name City State
United States Virginia Commonwealth University Richmond Virginia

Sponsors (2)

Lead Sponsor Collaborator
CMV Research Foundation International AIDS Vaccine Initiative

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Safety To evaluate the safety and tolerability, in adults without prior HCMV immunity (seronegative), of four live attenuated HCMV investigational vaccines at each of three dose levels. 2 years Yes
See also
  Status Clinical Trial Phase
Recruiting NCT01248598 - The Prevelance Rate of Human Cytomegalovirus (HCMV), Epstein-Barr Virus (EBV) and Human Herpes Virus (HHV-6) in a Saliva of the Patient With Periodantitis N/A
Active, not recruiting NCT05575492 - A Study of mRNA-1647 Cytomegalovirus Vaccine in Healthy Participants 9 to 15 Years of Age and Participants 16 to 25 Years of Age Phase 1/Phase 2
Recruiting NCT03665675 - Donor Virus-Specific CMV or AdV CTL to Treat CMV or AdV Reactivation or Disease After Solid Organ or HCT Early Phase 1
Completed NCT00456664 - CMV Disease and IRIS in HIV-1 Infected Persons N/A
Completed NCT04840199 - A Study to Evaluate the Anti-inflammatory Effects of Letermovir (Prevymis) in Adults With Human Immunodeficiency Virus (HIV)-1 and Asymptomatic Cytomegalovirus (CMV) Who Are on Suppressive Antiretroviral Therapy, Plus Its Effect on Chronic Inflammation, HIV Persistence and Other Clinical Outcomes. Phase 2
Active, not recruiting NCT05397223 - A Study of Modified mRNA Vaccines in Healthy Adults Phase 1
Completed NCT02452229 - Review of Human Herpes Viruses in Burns N/A
Completed NCT01160081 - Seroprevalence Study of Hepatitis A, Varicella-Zoster, Cytomegalovirus, Herpes Simplex and Bordetella Pertussis N/A
Completed NCT00467532 - Effect of Burn Size on Cytomegalovirus Reactivation and Correlates of T Cell Immune Function in Burned Patients N/A
Terminated NCT03127787 - Clinical Performance Evaluation of DxN CMV Assay
Completed NCT00366717 - Cytomegalovirus Reactivation in Cancer Patients Receiving Chemotherapy N/A
Completed NCT00815802 - Detection of Human Cytomegalovirus in the Saliva N/A
Completed NCT01646645 - Primary Transplant Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Suspended NCT00668798 - Cytomegalovirus (CMV) Transmission by Frozen Breast Milk in Preterms N/A
Completed NCT00214240 - The Impact of Cytogam® on Time to Viral Load Reduction in Kidney or Kidney/Pancreas Transplant Recipients With Clinical CMV Disease N/A
Completed NCT00330018 - Valganciclovir in Prevention of Cytomegalovirus (CMV) Reactivation Following Allogeneic-Stem Cell Transplantation (SCT) Phase 3
Completed NCT02083042 - Clinical Validation of Lophius Biosciences Kit T-Track® CMV in Kidney Transplant Recipients N/A
Completed NCT01895049 - Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria Phase 4
Completed NCT01162330 - The Benefits Feasibility and Acceptability of Extended Screening Testing in Newborn Babies Who Are Referred for Further Hearing Assessment N/A
Completed NCT01008540 - Prospective Multicentric Study of Cytomegalovirus Resistance in Transplant Patients and Bone Marrow Recipients N/A